The CAT (COPD Assessment Test) questionnaire as a predictor of the evolution of severe COPD exacerbations

被引:43
作者
Garcia-Sidro, Patricia [1 ]
Naval, Elsa [2 ]
Martinez Rivera, Carlos [3 ]
Bonnin-Vilaplana, Marc [4 ]
Luis Garcia-Rivero, Juan [5 ]
Herrejon, Alberto [6 ]
Malo de Molina, Rosa [7 ]
Jorge Marcos, Pedro [8 ]
Mayoralas-Alises, Sagrario [9 ]
Antonio Ros, Jose [10 ]
Valle, Manuel [7 ]
Esquinas, Cristina [11 ]
Barrecheguren, Miriam [11 ]
Miravitlles, Marc [11 ]
机构
[1] Univ Hosp La Plana, Vila Real, Spain
[2] Hosp La Ribera, Alzira, Spain
[3] Hosp Badalona Germans Trias & Pujol, Barcelona, Spain
[4] Fundacio Salut Emporda, Figueres, Spain
[5] Reg Hosp Laredo, Santander, Spain
[6] Hosp Dr Peset, Valencia, Spain
[7] Puerta Hierro Hosp, Majadahonda, Spain
[8] Univ A Coruna UDC, CHUAC Sergas, Inst Invest Biomed A Coruna INIBIC, Dept Pneumol, La Coruna, Spain
[9] Hosp Ramon & Cajal, E-28034 Madrid, Spain
[10] Hosp Virgen Arrixaca, Murcia, Spain
[11] Hosp Univ Vall Hebron, CIBER Enfermedades Resp CIBERES, Dept Pneumol, Barcelona 08035, Spain
关键词
COPD; CAT; Exacerbations; OBSTRUCTIVE PULMONARY-DISEASE; CLINICAL-OUTCOMES; HEALTH-STATUS; EPIDEMIOLOGY; VALIDATION; VALIDITY; THERAPY; COSTS; CCQ;
D O I
10.1016/j.rmed.2015.10.011
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: Since exacerbations of chronic obstructive pulmonary disease (COPD) cause both a great impact on the progression of the disease and generate high health expenditures, there is a need to develop tools to evaluate their prognosis. Method: Multicenter, observational, prospective study that evaluated the prognostic utility of the COPD Assessment Test (CAT) in severe exacerbations of COPD. Anthropometric and clinical variables were analyzed: smoking, history of exacerbations during the previous year, drug treatment, degree of baseline dyspnea, comorbidities; laboratory variables at admission (complete blood count, arterial blood gas and biochemistry) and CAT scores in the first 24 h of admission, on the third day, at discharge and at 3 months. Results: We evaluated 106 patients (91 males) with a mean age of 71.1 (SD 9.8 years), mean FEV1 45.2% (14.7%) and average CAT score at admission of 24.7 points (7.1). At three months after discharge, treatment failure was observed in 39 (36.8%) patients: 14 (13.2%) presented an exacerbation without the need for hospital admission, 22 were readmitted (20.8%) and 3 (2.8%) died during follow-up. The three factors associated with increased risk of failure were a reduction less than 4 units in the CAT at discharge compared to admission, lower hemoglobin levels and treatment with domiciliary oxygen. Conclusions: A change of <= 4 points in the CAT score at discharge compared to that obtained at admission due to a severe exacerbation of COPD, helps to predict therapeutic failure such as a new exacerbation, readmission or death in the subsequent three months. (C) 2015 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1546 / 1552
页数:7
相关论文
共 37 条
  • [1] Is The CAT Questionnaire Sensitive To Changes In Health Status In Patients With Severe COPD Exacerbations?
    Agusti, Alvar
    Soler, Juan J.
    Molina, Jesus
    Munoz, Maria Jose
    Garcia-Losa, Manuel
    Roset, Montserrat
    Jones, Paul W.
    Badia, Xavier
    [J]. COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2012, 9 (05) : 492 - 498
  • [2] Factors associated with hospital admission for exacerbation of chronic obstructive pulmonary disease
    Alcazar, Bernardino
    Garcia-Polo, Cayo
    Herrejon, Alberto
    Alberto Ruiz, Luis
    de Miguel, Javier
    Antonio Ros, Jose
    Garcia-Sidro, Patricia
    Tirado Conde, Gema
    Luis Lopez-Campos, Jose
    Martinez, Carlos
    Costan, Joaquin
    Bonnin, Marc
    Mayoralas, Sagrario
    Miravitlles, Marc
    [J]. ARCHIVOS DE BRONCONEUMOLOGIA, 2012, 48 (03): : 70 - 76
  • [3] Health status during hospitalisations for chronic obstructive pulmonary disease exacerbations: the validity of the Clinical COPD Questionnaire
    Antoniu, Sabina A.
    Puiu, Alina
    Zaharia, Bogdan
    Azoicai, Doina
    [J]. EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2014, 14 (02) : 283 - 287
  • [4] Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease
    Bestall, JC
    Paul, EA
    Garrod, R
    Garnham, R
    Jones, PW
    Wedzicha, JA
    [J]. THORAX, 1999, 54 (07) : 581 - 586
  • [5] Prognostic value of the hematocrit in patients with severe COPD receiving long-term oxygen therapy
    Chambellan, A
    Chailleux, E
    Similowski, T
    [J]. CHEST, 2005, 128 (03) : 1201 - 1208
  • [6] Bacterial Infection, Airway and Systemic Inflammation and Clinical Outcomes before and after Treatment of AECOPD, a Longitudinal and Cross-sectional Study
    Chang, Chun
    Zhu, Hong
    Shen, Ning
    Chen, Yahong
    He, Bei
    Zhao, Jiangchao
    Yao, Wanzhen
    [J]. COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2015, 12 (01) : 19 - 30
  • [7] Epidemiology and costs of chronic obstructive pulmonary disease
    Chapman, KR
    Mannino, DM
    Soriano, B
    Vermeire, PA
    Buist, AS
    Thun, MJ
    Connell, C
    Jemal, A
    Lee, TA
    Miravitlles, M
    Aldington, S
    Beasley, R
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2006, 27 (01) : 188 - 207
  • [8] A NEW METHOD OF CLASSIFYING PROGNOSTIC CO-MORBIDITY IN LONGITUDINAL-STUDIES - DEVELOPMENT AND VALIDATION
    CHARLSON, ME
    POMPEI, P
    ALES, KL
    MACKENZIE, CR
    [J]. JOURNAL OF CHRONIC DISEASES, 1987, 40 (05): : 373 - 383
  • [9] The COPD assessment test (CAT): response to pulmonary rehabilitation. A multicentre, prospective study
    Dodd, James W.
    Hogg, Lauren
    Nolan, Jane
    Jefford, Helen
    Grant, Amy
    Lord, Victoria M.
    Falzon, Christine
    Garrod, Rachel
    Lee, Cassandra
    Polkey, Michael I.
    Jones, Paul W.
    Man, William D-C
    Hopkinson, Nicholas S.
    [J]. THORAX, 2011, 66 (05) : 425 - 429
  • [10] Health-related QOL in acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease: A review of the literature
    Doll, H
    Miravitlles, M
    [J]. PHARMACOECONOMICS, 2005, 23 (04) : 345 - 363